UPMC Enterprises
VC Fund
Pittsburgh, United States
UPMC Enterprises is a VC fund in Pittsburgh focused on Health Care and Medical. UPMC Enterprises offers smart integration of technology needed to solve the complex problems facing the health care industry. At UPMC Enterprises, they help create health care innovations that will impact the lives of patients in meaningful, lasting ways. To deliver on this promise, they’ve chosen a few focus areas where their insights about healthcare’s future give us a unique advantage.They’ve built an impressive team with expertise in health care investing that’s second to none. When they choose to work with an entrepreneur, they work side by side with them and provide full access to UPMC’s vast resources.As an organization dedicated to Life Changing Medicine, UPMC has defined a bold mission: to shape the future of health care through innovation. At UPMC Enterprises, they help bring this mission to life by turning innovative ideas into growing, thriving businesses. That’s why they want the best to choose UPMC Enterprises. They wouldn’t have it any other way.
- Total investments:
- 50
- Last investment:
- Lead investor:
- 26%
Last updated:
For AI agents: llms.txt
Industries UPMC Enterprises invests in
Stages UPMC Enterprises invests in
Countries UPMC Enterprises invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brian Susko
|
|||
Mary Beth Navarra-Sirio
|
|||
|
Nancy Zimmerman
|
|||
Brad Ryan
|
|||
|
David Gibson
|
|||
| See all 6 contacts → | |||
Investment Focus
Industry
- Health Care 26 (52%)
- Medical 13 (26%)
- Biotechnology 11 (22%)
- Artificial Intelligence 6 (12%)
- Software 5 (10%)
Stage
- Series A 13 (26%)
- Series B 13 (26%)
- Series C 5 (10%)
- Venture - Series Unknown 4 (8%)
- Seed 3 (6%)
Country
- United States 26 (52%)
- France 2 (4%)
- Canada 1 (2%)
- Switzerland 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Brian Susko
Vice President, Engineering & Product Development
|
Vice President, Engineering & Product Development | Total investments: 0 | Find email | |
|
Mary Beth Navarra-Sirio
Vice President of Product Management and Market Development
|
Vice President of Product Management and Market Development | Total investments: 0 | Find email | |
|
Nancy Zimmerman
Executive In Residence
|
Executive In Residence | Total investments: 0 | Find email | |
|
Brad Ryan
Executive In Residence
|
Executive In Residence | Total investments: 0 | Find email | |
|
David Gibson
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cerevance
|
Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, thecompany generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders. | $20M / Series C / May 12, 2026 | |
Koda Health
|
Koda Health offers digital health tools and services focused on advance care planning and kidney care. The company provides a platform that guides patients through defining and documenting their medical care preferences for serious illness, and supports coordination for those with chronic kidney disease. It integrates with electronic medicalrecords (EMRs) using standards like HL7 FHIR to share patient directives securely. Koda Health also uses risk models to identify patients with complex health needs and connects them to patient advocate support. The company emphasizes user-friendly interfaces, video explainers, and interactive value identification to help individuals understand treatment options and communicate their wishes. | Series A / Apr 28, 2026 | |
RAAPID INC
|
RAAPID is a full-stack, end-to-end risk adjustment platform. We deliver guaranteed compliant ROI, reduce costs, improve accuracy, reduce physician abrasion, and mitigate the risk in OIG and RADV audits while running a successful risk adjustment program. We offer audit, retrospective & prospective risk adjustment solutions by augmentingnear-human reasoning with Neuro-Symbolic AI as an AI assistant to coders and providers. | Series A / Mar 18, 2026 | |
GenSight Biologics
|
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.Based on recent results obtained by the teams of its scientificfounders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness. | $2M / Post-IPO Equity / Mar 10, 2026 | |
BrainCheck
|
BrainCheck is a mobile interactive test for cognitive health. BrainCheck allows users to track their brain health for significant changes and share results with clinicians.BrainCheck is the result of 20 years of research conducted at the Eagleman Laboratory for Perception and Action at the Baylor College of Medicine. Dr. David Eagleman has beenstudying and creating reliable, noninvasive ways to understand the inner workings of the brain and assess brain function with innovative neurocognitive testing.BrainCheck’s goal is to help people understand what’s happening in their brains. When using one of their products, they can log their cognitive health data and track changes in their performance over time. They can also compare data to the general population’s results whatever their concern—after a concussion, at the onset of dementia, or other conditions that impair cognitive performance. BrainCheck encourages its user to use their data to have productive conversations with their physician about their brain health.BrainCheck empowers everyday people with data and empowers scientists to innovate. | $13M / Series A / Feb 26, 2026 | |
|
BrainCheck
|
BrainCheck is a mobile interactive test for cognitive health. BrainCheck allows users to track their brain health for significant changes and share results with clinicians.BrainCheck is the result of 20 years of research conducted at the Eagleman Laboratory for Perception and Action at the Baylor College of Medicine. Dr. David Eagleman has beenstudying and creating reliable, noninvasive ways to understand the inner workings of the brain and assess brain function with innovative neurocognitive testing.BrainCheck’s goal is to help people understand what’s happening in their brains. When using one of their products, they can log their cognitive health data and track changes in their performance over time. They can also compare data to the general population’s results whatever their concern—after a concussion, at the onset of dementia, or other conditions that impair cognitive performance. BrainCheck encourages its user to use their data to have productive conversations with their physician about their brain health.BrainCheck empowers everyday people with data and empowers scientists to innovate. | $13M / Series A / Feb 26, 2026 | |
Precede Biosciences
|
Precede Biosciences is breaking down the barriers to precision medicine by redefining what can be gleaned from a simple blood draw. Precede aims to increase drug development success rates and to contribute to a future in which every patient can receive a speedy, minimally invasive diagnosis and therapy tailored to the biology of their condition. | $63.5M / Series B / Jan 12, 2026 | |
|
Koda Health
|
Koda Health offers digital health tools and services focused on advance care planning and kidney care. The company provides a platform that guides patients through defining and documenting their medical care preferences for serious illness, and supports coordination for those with chronic kidney disease. It integrates with electronic medicalrecords (EMRs) using standards like HL7 FHIR to share patient directives securely. Koda Health also uses risk models to identify patients with complex health needs and connects them to patient advocate support. The company emphasizes user-friendly interfaces, video explainers, and interactive value identification to help individuals understand treatment options and communicate their wishes. | $7M / Series A / Oct 02, 2025 | |
Penguin Ai
|
Penguin AI uses AI to analyze health records and support care decisions, improving patient outcomes. | $25M / Series A / Sep 11, 2025 | |
Ultromics
|
Ultromics develops AI-powered software solutions to assist in cardiovascular disease diagnosis through echocardiography. The company provides platforms that support clinicians in interpreting echocardiogram data by applying machine learning to detect patterns and abnormalities that may indicate heart conditions. Ultromics offers its flagshipproduct, EchoGo, which automates the analysis of echocardiograms and delivers quantitative reports on cardiac function and structure. The software integrates with existing clinical workflows and is designed to enhance decision-making consistency while reducing variability in scan interpretation. Ultromics focuses on leveraging data-driven approaches to support early detection of conditions such as heart failure and coronary artery disease. Its technology is built on research collaborations and large-scale clinical datasets, aiming to improve diagnostic outcomes and support clinical efficiency. | $55M / Series C / Jul 31, 2025 | |
| See all 50 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does UPMC Enterprises invest in?
UPMC Enterprises invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 50 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact UPMC Enterprises?
Public channels for UPMC Enterprises include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at UPMC Enterprises?
The team at UPMC Enterprises includes Brian Susko (Vice President, Engineering & Product Development), Mary Beth Navarra-Sirio (Vice President of Product Management and Market Development) and Nancy Zimmerman (Executive In Residence), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
